Transversus Thoracic Muscle Plane Block Versus Pectointercostal Fascial Block for Enhanced Recovery After Cardiac Surgery

NCT07417462 | Recruiting

• 1 other identifier: 04-2026-300789
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

This work aims to assess the analgesic efficacies of transversus thoracic muscle plane block (TTPB) and transversus thoracic muscle plane block (TTPB) for open cardiac surgeries

Conditions

Transversus Thoracic Muscle Plane Block; Pecto-intercostal Fascial Block; Enhanced Recovery; Cardiac Surgery

Outcome Measures

Primary Outcomes (1)

• Total amount analgesic requirement

  In cases where rescue analgesia is required \[numerical rating scale (NRS) ≥4\], intravenous Nalbuphine 0.1 mg/kg will be given.

  24 hours postoperatively

Secondary Outcomes (8)

• Degree of pain

  24 hours postoperatively

• The number of patients required rescue analgesia

  24 hours postoperatively

• Postoperative nausea and vomiting (PONV)

  24 hours postoperatively

• Time to extubation

  24 hours postoperatively

• Length of stay in the intensive care unit.

  Average 7 days postoperatively

Study Arms (3)

Group PIFB

EXPERIMENTAL

Patients will receive pecto-intercostal fascial block intraoperatively (20 ml of bupivacaine 0.25% + 1 ml dexamethasone 8 mg).

Other: Pecto-intercostal fascial block

Group TTPB

EXPERIMENTAL

Patients will receive transversus thoracic muscle plane block was performed intraoperatively (20 ml of bupivacaine 0.25% + 1 ml dexamethasone 8 mg).

Other: Transversus thoracic muscle plane block

Control Group

SHAM COMPARATOR

Patients will receive bilateral superficial needle puncture at a location like transversus thoracic muscle plane block without any solution injected. Only 25 saline will be injected superficially.

Other: Sham (No Treatment)

Interventions

Pecto-intercostal fascial block OTHER

Patients will receive pecto-intercostal fascial block intraoperatively (20 ml of bupivacaine 0.25% + 1 ml dexamethasone 8 mg).

Group PIFB

Transversus thoracic muscle plane block OTHER

Patients will receive transversus thoracic muscle plane block was performed intraoperatively (20 ml of bupivacaine 0.25% + 1 ml dexamethasone 8 mg).

Group TTPB

Sham (No Treatment) OTHER

Patients will receive bilateral superficial needle puncture at a location like transversus thoracic muscle plane block without any solution injected. Only 25 saline will be injected superficially.

Control Group

Eligibility Criteria

• Age: 40 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Age from 40 to 60 years.
• Both sexes.
• American Society of Anesthesiology (ASA) physical status II-III.
• Body mass index (BMI) \< 35 kg/m2.
• Underwent cardiac surgery (coronary artery bypass graft surgery with median sternotomy).

You may not qualify if:

• Valve replacement procedures.
• Emergency operations.
• Redo surgeries.
• Minimally invasive approaches.
• The presence of psychiatric disorders.
• Cognitive impairment preventing accurate assessment using the verbal numerical rating scale (NRS).
• Known hypersensitivity or a history of allergy to local anesthetics.
• Had severe major organ dysfunction.
• Left ventricular ejection fraction below 30%.
• Pregnancy or breastfeeding.

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut University

Asyut, 71515, Egypt

RECRUITING

MeSH Terms

Interventions

salicylhydroxamic acid

Central Study Contacts

Noha H Abdelghany, MD

CONTACT

+966545945924; nohadaghash@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Anesthesia & ICU, Faculty of Medicine, Assiut University

Study Record Dates

• First Submitted: February 11, 2026
• First Posted: February 18, 2026
• Study Start: February 18, 2026
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: February 19, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)